{"id":"W3132547876","doi":"10.1158/1538-7445.sabcs20-ps12-28","title":"Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Taxane; Medicine; Triple-negative breast cancer; Internal medicine; Oncology; Metastatic breast cancer; Phases of clinical research; Chemotherapy; Population; Breast cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001730015,0.0004347033,0.00103311,0.0003956419,0.0004011291,0.00006571679,0.0002647612,0.0001049268,0.0009832811],"category_scores_gemma":[0.00106211,0.0003860881,0.0001602789,0.001308372,0.0004054167,0.0003878147,0.0001253702,0.0006734577,0.000006141269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007806933,"about_ca_system_score_gemma":0.002334839,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001775863,"about_ca_topic_score_gemma":0.00122161,"domain_scores_codex":[0.99524,0.0003882494,0.0009063256,0.001005927,0.001567952,0.0008915842],"domain_scores_gemma":[0.9940634,0.001093709,0.0004303915,0.0006797753,0.003374441,0.0003582253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05358638,0.008349481,0.002499994,0.001448478,0.001253296,0.0002524981,0.006443326,0.000562357,0.08296684,0.00007003617,0.0003393033,0.842228],"study_design_scores_gemma":[0.5308836,0.04282075,0.1027773,0.007400133,0.0007913897,0.0004627479,0.03246831,0.00761193,0.2604142,0.008157253,0.004159576,0.002052858],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764498,0.01158083,0.0005256411,0.003639068,0.0002074552,0.005852323,0.001643605,0.00005485029,0.00004641594],"genre_scores_gemma":[0.9891009,0.003889555,0.0008795607,0.0002539302,0.0002269911,0.004760704,0.0001727194,0.0001191728,0.0005964499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8401752,"threshold_uncertainty_score":0.99993,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.159363250679661,"score_gpt":0.5174108302588322,"score_spread":0.3580475795791712,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}